Suppression of NF-κB signaling and NLRP3 inflammasome activation in macrophages is responsible for the amelioration of experimental murine colitis by the natural compound fraxinellone

Toxicology and Applied Pharmacology

Volumn 281, Issue 1, 2014, Pages 146-156

  Wu, Xue Feng ^a   Ouyang, Zi Jun ^a   Feng, Li Li ^a   Chen, Gong ^a   Guo, Wen Jie ^a   Shen, Yan ^a   Wu, Xu Dong ^a   Sun, Yang ^a   Xu, Qiang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Experimental colitis; Fraxinellone; Inflammatory bowel disease; Macrophages; NF B; NLRP3 inflammasome

Indexed keywords

3 (FURAN 3 YL) 3A,7 DIMETHYL 3A,4,5,6 TETRAHYDROISOBENZOFURAN 1(3H) ONE; ALKALINE PHOSPHATASE; ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CRYOPYRIN; CYCLOOXYGENASE 2; DEXAMETHASONE; DEXTRAN SULFATE; GASTROINTESTINAL AGENT; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOPEROXIDASE; NATURAL PRODUCT; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; BENZOFURAN DERIVATIVE; FRAXINELLONE; NLRP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CELL LEVEL; COLON; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL COLITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PERITONEUM MACROPHAGE; SIGNAL TRANSDUCTION; TISSUE LEVEL; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; COLITIS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; BENZOFURANS; CELL LINE; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMASOMES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; SIGNAL TRANSDUCTION;

EID: 84908352199     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.10.002     Document Type: Article

References (55)

1. Ahmad I., Muneer K.M., Tamimi I.A., Chang M.E., Ata M.O., Yusuf N. Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. Toxicol. Appl. Pharmacol. 2013, 270:70-76.
2. Alex P., Zachos N.C., Nguyen T., Gonzales L., Chen T.E., Conklin L.S., Centola M., Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 2009, 15:341-352.
3. Bhuta T., Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch. Dis. Child Fetal Neonatal Ed. 1998, 79:F26-F33.
4. Biasi F., Leonarduzzi G., Oteiza P.I., Poli G. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid. Redox Signal. 2013, 19:1711-1747.
5. Burisch J., Pedersen N., Cukovic-Cavka S., Brinar M., Kaimakliotis I., Duricova D., Shonova O., Vind I., Avnstrom S., Thorsgaard N., Andersen V., Krabbe S., Dahlerup J.F., Salupere R., Nielsen K.R., Olsen J., Manninen P., Collin P., Tsianos E.V., Katsanos K.H., Ladefoged K., Lakatos L., Bjornsson E., Ragnarsson G., Bailey Y., Odes S., Schwartz D., Martinato M., Lupinacci G., Milla M., De Padova A., D'Inca R., Beltrami M., Kupcinskas L., Kiudelis G., Turcan S., Tighineanu O., Mihu I., Magro F., Barros L.F., Goldis A., Lazar D., Belousova E., Nikulina I., Hernandez V., Martinez-Ares D., Almer S., Zhulina Y., Halfvarson J., Arebi N., Sebastian S., Lakatos P.L., Langholz E., Munkholm P. East-West Gradient in the Incidence of Inflammatory Bowel Disease in Europe: the ECCO-EpiCom Inception Cohort. Gut 2014, 63:588-597.
6. Burns R.C., Rivera-Nieves J., Moskaluk C.A., Matsumoto S., Cominelli F., Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001, 121:1428-1436.
7. Camuesco D., Comalada M., Rodriguez-Cabezas M.E., Nieto A., Lorente M.D., Concha A., Zarzuelo A., Galvez J. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br. J. Pharmacol. 2004, 143:908-918.
8. Cenac N., Coelho A.M., Nguyen C., Compton S., Andrade-Gordon P., MacNaughton W.K., Wallace J.L., Hollenberg M.D., Bunnett N.W., Garcia-Villar R., Bueno L., Vergnolle N. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 2002, 161:1903-1915.
9. Chen H.W., Kuo H.T., Wang S.J., Lu T.S., Yang R.C. In vivo heat shock protein assembles with septic liver NF-kappaB/I-kappaB complex regulating NF-kappaB activity. Shock 2005, 24:232-238.
10. Chen M., Wang H., Chen W., Meng G. Regulation of adaptive immunity by the NLRP3 inflammasome. Int. Immunopharmacol. 2011, 11:549-554.
11. Cheng C.C., Chen Y.H., Chang W.L., Yang S.P., Chang D.M., Lai J.H., Ho L.J. Phytoestrogen bavachin mediates anti-inflammation targeting Ikappa B kinase-I kappaB alpha-NF-kappaB signaling pathway in chondrocytes in vitro. Eur. J. Pharmacol. 2010, 636:181-188.
12. Crom D.B. Dexamethasone sodium phosphate ophthalmic (Decadron): a review of its use, and guidelines administration. J. Ophthalmic. Nurs. Technol. 1982, 1:48-49.
13. Danese S., Malesci A., Vetrano S. Colitis-associated cancer: the dark side of inflammatory bowel disease. Gut 2011, 60:1609-1610.
14. Dejardin E., Deregowski V., Chapelier M., Jacobs N., Gielen J., Merville M.P., Bours V. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999, 18:2567-2577.
15. Giamarellos-Bourboulis E.J., van de Veerdonk F.L., Mouktaroudi M., Raftogiannis M., Antonopoulou A., Joosten L.A., Pickkers P., Savva A., Georgitsi M., van der Meer J.W., Netea M.G. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit. Care 2011, 15:R27.
16. Gross O., Yazdi A.S., Thomas C.J., Masin M., Heinz L.X., Guarda G., Quadroni M., Drexler S.K., Tschopp J. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012, 36:388-400.
17. Guo Y., Yan Y., Yu X., Wang Y., Zhi X.Y., Hu Y., Xu H. Synthesis and insecticidal activity of some novel fraxinellone-based esters. J. Agric. Food Chem. 2012, 60:7016-7021.
18. Heid M.E., Keyel P.A., Kamga C., Shiva S., Watkins S.C., Salter R.D. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J. Immunol. 2013, 191:5230-5238.
19. Hirota S.A., Ng J., Lueng A., Khajah M., Parhar K., Li Y., Lam V., Potentier M.S., Ng K., Bawa M., McCafferty D.M., Rioux K.P., Ghosh S., Xavier R.J., Colgan S.P., Tschopp J., Muruve D., MacDonald J.A., Beck P.L. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 2011, 17:1359-1372.
20. Indar A.A., Young-Fadok T.M., Heppell J., Efron J.E. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. World J. Surg. 2009, 33:1049-1052.
21. Joosten L.A., Ea H.K., Netea M.G., Busso N. Interleukin-1beta activation during acute joint inflammation: a limited role for the NLRP3 inflammasome in vivo. Joint Bone Spine 2011, 78:107-110.
22. Keklikoglu N., Koray M., Kocaelli H., Akinci S. iNOS expression in oral and gastrointestinal tract mucosa. Dig. Dis. Sci. 2008, 53:1437-1442.
23. Kim J.H., Park Y.M., Shin J.S., Park S.J., Choi J.H., Jung H.J., Park H.J., Lee K.T. Fraxinellone inhibits lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by negatively regulating nuclear factor-kappa B in RAW 264.7 macrophages cells. Biol. Pharm. Bull. 2009, 32:1062-1068.
24. Kim S.J., Lee S.M. NLRP3 inflammasome activation in d-galactosamine and lipopolysaccharide-induced acute liver failure: role of heme oxygenase-1. Free Radic. Biol. Med. 2013, 65:997-1004.
25. Klebl F.H., Olsen J.E., Jain S., Doe W.F. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine. J. Pathol. 2001, 195:609-615.
26. Lim S., Kang K.W., Park S.Y., Kim S.I., Choi Y.S., Kim N.D., Lee K.U., Lee H.K., Pak Y.K. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase expression by a novel compound, mercaptopyrazine, through suppression of nuclear factor-kappaB binding to DNA. Biochem. Pharmacol. 2004, 68:719-728.
27. Liu H., Xu R., Feng L., Guo W., Cao N., Qian C., Teng P., Wang L., Wu X., Sun Y., Li J., Shen Y., Xu Q. A novel chromone derivative with anti-inflammatory property via inhibition of ROS-dependent activation of TRAF6-ASK1-p38 pathway. PLoS ONE 2012, 7:e37168.
28. Liu J., Wang Y., Ouyang X. Beyond Toll-like receptors: Porphyromonas gingivalis induces IL-6, IL-8, and VCAM-1 expression through NOD-mediated NF-kappaB and ERK signaling pathways in periodontal fibroblasts. Inflammation 2014, 37:522-533.
29. Liu W., Guo W., Wu J., Luo Q., Tao F., Gu Y., Shen Y., Li J., Tan R., Xu Q., Sun Y. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem. Pharmacol. 2013, 85:1504-1512.
30. Maaser C., Schoeppner S., Kucharzik T., Kraft M., Schoenherr E., Domschke W., Luegering N. Colonic epithelial cells induce endothelial cell expression of ICAM-1 and VCAM-1 by a NF-kappaB-dependent mechanism. Clin. Exp. Immunol. 2001, 124:208-213.
31. Mahida Y.R., Rolfe V.E. Host-bacterial interactions in inflammatory bowel disease. Clin. Sci. (Lond.) 2004, 107:331-341.
32. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997, 278:860-866.
33. Nahidi L., Leach S.T., Mitchell H.M., Kaakoush N.O., Lemberg D.A., Munday J.S., Huinao K., Day A.S. Inflammatory bowel disease therapies and gut function in a colitis mouse model. Biomed. Res. Int. 2013, 2013:909613.
34. Patel M.A., Patel P.K., Patel M.B. Effects of ethanol extract of Ficus bengalensis (bark) on inflammatory bowel disease. Indian J. Pharmacol. 2010, 42:214-218.
35. Petrilli V., Papin S., Tschopp J. The inflammasome. Curr. Biol. 2005, 15:R581.
36. Piplani H., Vaish V., Sanyal S.N. Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-kappaB and an inflammatory protein, iNOS. Eur. J. Cancer Prev. 2012, 21:511-522.
37. Ponder A., Long M.D. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol 2013, 5:237-247.
38. Turner D., Lev-Tzion R. Understanding infliximab in Crohn's disease: the long-term outcomes. Dig. Dis. Sci. 2013, 58:604-607.
39. Salim S.Y., Soderholm J.D. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm. Bowel Dis. 2011, 17:362-381.
40. Sedimbi S.K., Hagglof T., Karlsson M.C. IL-18 in inflammatory and autoimmune disease. Cell. Mol. Life Sci. 2013, 70:4795-4808.
41. Sun Y., Qin Y., Gong F.Y., Wu X.F., Hua Z.C., Chen T., Xu Q. Selective triggering of apoptosis of concanavalin A-activated T cells by fraxinellone for the treatment of T-cell-dependent hepatitis in mice. Biochem. Pharmacol. 2009, 77:1717-1724.
42. Sun Y., Wu X.X., Yin Y., Gong F.Y., Shen Y., Cai T.T., Zhou X.B., Wu X.F., Xu Q. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. Biochem. Pharmacol. 2010, 79:229-238.
43. Trevisin M., Pollock W., Dimech W., Savige J. Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD). J. Immunol. Methods 2008, 336:104-112.
44. Watanabe R., Azuma R.W., Suzuki J.I., Ogawa M., Itai A., Hirata Y., Komuro I., Isobe M. Inhibition of NF-kappaB activation by a novel IKK inhibitor reduces the severity of experimental autoimmune myocarditis via suppression of T-cell activation. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:1761-1771.
45. Wejman J., Bielecki K., Ostrowska J., Baczuk L., Perkowska-Ptasinska A., Tarnowski W. Pathological analysis of lesions within intestines resected due to ulcerative colitis. Pol. J. Pathol. 2006, 57:113-116.
46. Wendelsdorf K., Bassaganya-Riera J., Hontecillas R., Eubank S. Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease. J. Theor. Biol. 2010, 264:1225-1239.
47. Willingham S.B., Allen I.C., Bergstralh D.T., Brickey W.J., Huang M.T., Taxman D.J., Duncan J.A., Ting J.P. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J. Immunol. 2009, 183:2008-2015.
48. Wu X.F., Wu X.X., Guo W.J., Luo Q., Gu Y.H., Shen Y., Tan R.X., Sun Y., Xu Q. Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes. Toxicol. Appl. Pharmacol. 2012, 263:296-302.
49. Xu G.L., Du Y.F., Cheng J., Huan L., Chen S.C., Wei S.H., Gong Z.N., Cai J., Qiu T., Wu H., Sun T., Ao G.Z. Inhibition of inflammatory mediators contributes to the anti-inflammatory activity of KYKZL-1 via MAPK and NF-kappaB pathway. Toxicol. Appl. Pharmacol. 2013, 272:221-229.
50. Yoon J.S., Sung S.H., Kim Y.C. Neuroprotective limonoids of root bark of Dictamnus dasycarpus. J. Nat. Prod. 2008, 71:208-211.
51. 2+ channel blockers. Naunyn Schmiedebergs Arch Pharmacol 1992, 345:349-355.
52. Yuan S., Zhang J., Zhang L., Huang L., Peng J., Huang S., Chen S., Xu A. The archaic roles of the amphioxus NF-kappaB/IkappaB complex in innate immune responses. J. Immunol. 2013, 191:1220-1230.
53. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997, 91:243-252.
54. Zheng J.J., Cu X.Q., Shi X.H., Wang Y.M., Jia L.M., Zhou X.L., Wang F.M. Colonoscopic and histologic features of colonic Crohn's disease in Chinese patients. J. Dig. Dis. 2007, 8:35-41.
55. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.